Sagimet Biosciences Inc. (SGMT) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in San Mateo, CA, United States. The current CEO is David A. Happel.
SGMT has IPO date of 2023-07-17, 14 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $177.38M.
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
